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Purpose: Long-term continuous imatinib is recommended for adult patients with unresectable and/or metastatic
KIT+ gastrointestinal stromal tumors (GIST) as long as the patient continues to benefit. In the adjuvant setting,
recent findings indicate that patients at considerable risk of recurrence should receive at least 3 years of imatinib.
Because imatinib is often administered for prolonged periods, proper management of imatinib-associated adverse
events is crucial.
Case report: We report a 56-year-old man with metastatic KIT+ GIST of the liver who had Grade 3 imatinib
intolerance (skin rash) when treatment was started. The rash was managed with antihistamine treatment
(Dexchlorpheniramine maleate 4 mg per day) and several temporary (up to 2 weeks) dose interruptions. The
patient’s skin rash partially improved, and he tolerated gradual reintroduction of imatinib over several months. The
patient maintained imatinib 400 mg/d, and tolerated it during the 2 years when he was on antihistamine
treatment. After 2 years, the patient continued imatinib therapy without having to take antihistamines. The patient
responded according to RECIST 1.1 and Choi to imatinib treatment for his metastatic GIST (partial response). As of
September, 2012, the patient has been on imatinib therapy for 131 months and remains progression free.
Conclusions: The results of this case report demonstrated that a patient with metastatic KIT+ GIST who was initially
intolerant to imatinib maintained, and responded to imatinib therapy after treatment of an imatinib-associated
adverse effect. These results suggest that initial intolerance to imatinib should not necessarily result in treatment
discontinuation, as these adverse effects, when managed properly, may be tolerated and may decrease over time.
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Imatinib mesylate is approved for the treatment of adult
patients with unresectable and/or metastatic KIT+
gastrointestinal stromal tumor (GIST) and for the adju-
vant treatment of adult patients following resection of
primary GIST [1]. Current treatment guidelines recom-
mend long-term continuous imatinib therapy in patients
with advanced GIST and at least 12 months of adju-
vant imatinib therapy for patients with a substantial
risk of relapse [2,3]. Recently reported results of the
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should be recommended in patients who have a con-
siderable risk of recurrence after surgery [4]. National
Comprehensive Cancer Network and ESMO Guide-
lines have recently been updated, based on the results
of the SSGXVIII/AIO trial, endorsing this recommen-
dation [5,6]. Because imatinib is often administered for
prolonged periods of time, close monitoring and proper
management of imatinib-associated adverse effects are
crucial. Imatinib is generally well tolerated, although
some patients have difficulty tolerating the standard
starting dose of 400 mg/d. Here, we report on a patient
with metastatic GIST who experienced skin toxicity in
response to imatinib at the beginning of standard ther-
apy. With prudent use of supportive care measures, theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Blay Clinical Sarcoma Research 2012, 2:23 Page 2 of 3
http://www.clinicalsarcomaresearch.com/content/2/1/23patient was able to continue imatinib therapy while
remaining progression free for more than 10 years.
Case presentation
A 56-year-old man with a disease diagnosis of primary
gastric GIST underwent complete en-bloc resection in
1998. Mutational analysis of the excised mass showed
that the tumor had a mutation in KIT exon 11 involving
codons 557 and 558. Based on the tumor size (7 cm)
and mitotic index (> 8 mitoses per 50 high-powered
field), the patient was considered at high risk for recur-
rence [7]. In 2000, the patient developed metastatic
GIST, and computed tomography (CT) scans revealed at
least 8 large masses in both liver lobes with the largest
liver mass measuring 8 cm. He was started on imatinib
400 mg/d in April 2001, but developed Grade 3 skin
rash after 4 weeks of imatinib therapy. The rash was
managed with antihistamine treatment (dexchlorphenir-
amine 4mg per day and oxatomide 60mg per day) and
several temporary dose interruptions (each dose inter-
ruption lasted for a few days to up to 2 weeks). After
each dose interruption, the patient was restarted on ima-
tinib 200 mg/d, then after 1 week, 300 mg/d, and
resumed taking standard-dose imatinib 400 mg/d after
9 weeks. The patient’s skin rash partially improved in
response to dexchlorpheniramine treatment and dose
interruption, and he maintained and tolerated imatinib
400 mg/d during the 2 years when he was on antihista-
mine treatment. After 2 years, although his skin rash
was not completely resolved, the patient was able to
continue imatinib therapy without having to take anti-
histamines. The patient responded to imatinib treatment
for his metastatic GIST in the liver. Tumors became
hypodense after 3 months of imatinib therapy (Figure 1),
indicating good response to imatinib according to Choi
criteria and Response Evaluation Criteria In Solid
Tumors (RECIST). After 122 months of treatment, a
partial response by RCIST and Choi criteria is stillBefore initiation of treatment a b
Figure 1 CT scans of the patient before and after imatinib treatment
the patient before initiation of imatinib treatment (a). The masses (arrow) b
imatinib treatment (b), indicating good response to imatinib.observed; liver masses had decreased in size from 8 to
5 cm. As of September, 2012, the patient has been on
imatinib therapy for more than 10 years and remains
progression free with normal physical examination.
This case report demonstrates that a patient with
metastatic GIST who has difficulty tolerating imatinib at
the standard treatment initiation dose (400 mg/d) can be
effectively managed with supportive care and dose
adjustments in order to maintain response to treatment.
This suggests that initial intolerance to imatinib should
not necessarily result in treatment discontinuation, as
some of these adverse effects, when managed properly,
can be tolerated and may decrease over time.
Maintaining continuous drug administration at a suffi-
ciently high dose is necessary for GIST patients to ob-
tain clinical benefit from imatinib [8,9]. However,
adverse effects may reduce patient compliance and the
clinical efficacy of the treatment. Although true imatinib
intolerance is very rare, short-term intolerance and dis-
comfort are not uncommon [10]. The most frequently
observed adverse effects, generally Grade 1 or 2, include
edema, gastrointestinal effects (diarrhea or nausea/
vomiting), skin rash, and fatigue. There are different
strategies for managing each imatinib-related adverse ef-
fect [10]. Skin rash, for example, which often occurs dur-
ing the first few months of treatment initiation, can be
managed with antihistamines and topical steroids [10].
In patients with severe skin reactions, dose reduction or
interruption of imatinib, and/or use of oral steroids may
be required [10]. Imatinib can be gradually reintroduced,
and many patients, like the patient described in this case
report, are eventually able to tolerate imatinib.
This patient has continued treatment with imatinib
and has remained disease free for more than 10 years.
This is one of the longest durations of imatinib treat-
ment for advanced KIT+ GIST reported in the literature.
Long-term follow-up results of a key trial in patients
with metastatic/advanced GIST (B2222 study) recently3 months after initiation of imatinib treatment
for metastatic GIST. Tumor masses (arrow) can be seen in the liver of
ecame hypodense and homogenous on CT obtained 3 months after
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the study remained on continuous imatinib at a median
follow-up time of 9.4 years (maximum 9.9 years) [11].
The results of this case report and the B2222 study
support the long-term efficacy of imatinib for the
treatment of patients with unresectable and/or meta-
static KIT+ GIST.
Conclusions
In conclusion, early recognition and proper manage-
ment of imatinib-associated adverse effects may help
GIST patients maintain imatinib therapy and ultim-
ately achieve optimal clinical efficacy.
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